Finite dimensional models of drug resistant and phase specific cancer chemotherapy

We consider the problem of modeling drug resistance and phase specificity of cancer chemotherapy using finite dimensional models. We formulate optimal control problems arising in protocol design for such models and discuss research issues resulting from such formulations. keywords: chemotherapy, drug resistance, phase specificity, biomathematical modeling, optimal control

[1]  Zvia Agur,et al.  Drug resistance as a dynamic process in a model for multistep gene amplification under various levels of selection stringency , 2004, Cancer Chemotherapy and Pharmacology.

[2]  H. Schattler,et al.  Optimal control for a bilinear model with recruiting agent in cancer chemotherapy , 2003, 42nd IEEE International Conference on Decision and Control (IEEE Cat. No.03CH37475).

[3]  Xin Lu,et al.  Optimal controls for a 3-compartment model for cancer chemotherapy with quadratic objective , 2003 .

[4]  Andrzej Świerniak,et al.  Different Models of Chemotherapy Taking Into Account Drug Resistance Stemming from Gene Amplification , 2003 .

[5]  Urszula Ledzewicz,et al.  OPTIMAL CONTROL FOR A CLASS OF COMPARTMENTAL MODELS IN CANCER CHEMOTHERAPY , 2003 .

[6]  H. Schattler,et al.  Sufficient conditions for optimality of controls in biomedical systems , 2002, Proceedings of the 41st IEEE Conference on Decision and Control, 2002..

[7]  Urszula Ledzewicz,et al.  ANALYSIS OF A CELL-CYCLE SPECIFIC MODEL FOR CANCER CHEMOTHERAPY , 2002 .

[8]  Urszula Ledzewicz,et al.  Optimal Bang-Bang Controls for a Two-Compartment Model in Cancer Chemotherapy , 2002 .

[9]  H. Schattler,et al.  Analysis of a class of optimal control problems arising in cancer chemotherapy , 2002, Proceedings of the 2002 American Control Conference (IEEE Cat. No.CH37301).

[10]  Marek Kimmel,et al.  Branching processes in biology , 2002 .

[11]  A. Świerniak,et al.  Cancer chemotherapy optimization under evolving drug resistance , 2001 .

[12]  Jaroslaw Smieja,et al.  Qualitative analysis of controlled drug resistance model - inverse Laplace and and semigroup approach , 1999 .

[13]  R. Kerbel.  A cancer therapy resistant to resistance , 1997, Nature.

[14]  D. Kirschner,et al.  A Mathematical Model of Combined Drug Therapy of HIV Infection , 1997 .

[15]  A Swierniak,et al.  Optimal control problems arising in cell‐cycle‐specific cancer chemotherapy , 1996, Cell proliferation.

[16]  Jaroslaw Smieja,et al.  Cell Cycle as an Object of Control , 1995 .

[17]  R. Bassanezi,et al.  Drug kinetics and drug resistance in optimal chemotherapy. , 1995, Mathematical biosciences.

[18]  Paul Calabresi,et al.  Medical Oncology: Basic Principles and Clinical Management of Cancer , 1993 .

[19]  Z. Agur,et al.  The dynamics of gene amplification described as a multitype compartmental model and as a branching process. , 1991, Mathematical biosciences.

[20]  G. W. Swan.  Role of optimal control theory in cancer chemotherapy. , 1990, Mathematical biosciences.

[21]  M Kimmel,et al.  Mathematical models of gene amplification with applications to cellular drug resistance and tumorigenicity. , 1990, Genetics.

[22]  J. Horton.  Medical Oncology: Basic Principles and Clinical Management of Cancer, , 1986 .

[23]  J. Goldie,et al.  A model for the resistance of tumor cells to cancer chemotherapeutic agents , 1983 .

[24]  R T Schimke,et al.  Relationship of amplified dihydrofolate reductase genes to double minute chromosomes in unstably resistant mouse fibroblast cell lines , 1981, Molecular and cellular biology.

[25]  R T Schimke,et al.  Loss and stabilization of amplified dihydrofolate reductase genes in mouse sarcoma S-180 cell lines , 1981, Molecular and cellular biology.

[26]  Martin M. Eisen,et al.  Mathematical Models in Cell Biology and Cancer Chemotherapy , 1979 .

[27]  M. L. Chambers.  The Mathematical Theory of Optimal Processes , 1965 .

[28]  L. S. Pontryagin,et al.  Mathematical Theory of Optimal Processes , 1962 .